Association of anaplastic lymphoma kinase variants and alterations with ensartinib response duration in non‐small cell lung cancer-Reference-Cited by-同舟云学术

Association of anaplastic lymphoma kinase variants and alterations with ensartinib response duration in non‐small cell lung cancer

Published:2021-07-20 Issue:17 Volume:12 Page:2388-2399
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thorac Cancer

Author:

Hou Donghui¹^ORCID,Zheng Xiaomin²,Song Wei³,Liu Xiaoqing⁴,Wang Sicong⁵,Zhou Lina¹,Tao Xiuli⁶,Lv Lv⁶,Sun Qi⁷,Jin Yujing⁶,Zhang Zewei⁶,Ding Lieming⁸,Wu Ning¹⁶,Zhao Shijun¹^ORCID

Affiliation:

1. Department of Diagnostic Radiology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China

2. Department of Endocrinology Chui Yang Liu Hospital affiliated to Tsinghua University Beijing China

3. Department of Radiology Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College Beijing China

4. Department of Pulmonary Oncology The Fifth Medical Centre, Chinese PLA General Hospital Beijing China

5. GE Healthcare, Life Sciences Beijing China

6. PET‐CT Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China

7. Department of Radiology Harbin Medical University Cancer Hospital Harbin China

8. Betta Pharmaceuticals Co., Ltd. Hangzhou China

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.14083

Reference37 articles.

1. Therapeutic Targeting of Anaplastic Lymphoma Kinase in Lung Cancer: A Paradigm for Precision Cancer Medicine